As part of the strategic realignment of its US business, the company has filed for voluntary liquidation under Chapter 7 of ...

A major scientific advance in protein modeling developed by Microsoft Research AI for Science, has been published in Science.

Wockhardt will exit its loss-making US generic business to focus on antibiotics and diabetes care. The company filed for ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

Satya Nadella has unveiled BioEmu, Microsoft's new AI initiative aimed at accelerating drug discovery processes.

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

Microsoft's BioEmu, an AI-driven model, decodes protein motion to enhance drug discovery, offering rapid insights into ...

Microsoft's CEO, Satya Nadella, has announced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding ...

Microsoft's CEO, Satya Nadella, has introduced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding protein motion.

Microsoft’s new AI system, Biomolecular Emulator-1 (BioEmu-1), will help decode protein motion and help in the faster ...

Microsoft’s new AI system BioEmu will help decode protein motion and help in faster discovery of drugs, said CEO Satya ...

Understanding protein motion is essential to understanding biology and advancing drug discovery,” said Nadella, in a post on ...